Some questions were asked on the chart thread re the launch, and...

Some questions were asked on the chart thread re the launch, and distribution of ZLD products. Rather than continue that discussion on the chart thread, I thought I would start a new one.

"Update on Australian Launch of Insomnia and HOPE products
Zelira is pleased to report it is on-track to launch its Zenivol™ and HOPE™ range of products into the
Australian market by the end of Q3 2020. Zelira has entered into the necessary manufacturing and
distribution agreements (see below), has finalised branding and packaging details and has engaged one
of Australia’s leading healthcare agencies who specialise in outsourced sales solutions to support the
company’s Australian launch of all three products.
This phase marks a major milestone for Zelira as it accelerates its transition from a purely research-based
organisation to become a revenue generating company."

"Manufacturing agreement with Tasmanian Alkaloids
In May 2020, Zelira announced it had entered into an agreement with Tasmanian Alkaloids (TasAlk) to
supply Zenivol™ and HOPE™ in the Asia Pacific (APAC) region. TasAlk is a global leader in the extraction
and purification of high-value plant-derived products for the pharmaceutical industry and has added
cannabinoid-derived medicinal products and services to its portfolio.
HOPE™ Packaging Zenivol™ Packaging
Under the agreement, TasAlk will have exclusive rights to manufacture and supply Zelira’s Insomnia and
HOPE™ formulations initially in the APAC region for three years. In Australia, all products will be supplied
to patients under the Australia Government TGA Special Access Scheme (SAS)."

The above is taken from the 4C report recently released.